Abstract:BACKGROUND: Most clinical opioids act through μ-opioid receptors. They effectively relieve pain but are limited by side effects, such as constipation, respiratory depression, dependence, and addiction. Many efforts have been made toward developing potent analgesics that lack side effects. Three-iodobenzoyl-6β-naltrexamide (IBNtxA) is a novel class of opioid active against thermal, inflammatory, and neuropathic pain, without respiratory depression, physical dependence, and reward behavior. The μ-opioid receptor (OPRM1) gene undergoes extensive alternative precursor messenger ribonucleic acid splicing, generating multiple splice variants that are conserved from rodents to humans. One type of variant is the exon 11 (E11)–associated truncated variant containing 6 transmembrane domains (6TM variant). There are 5 6TM variants in the mouse OPRM1 gene, including mMOR-1G, mMOR-1M, mMOR-1N, mMOR-1K, and mMOR-1L. Gene-targeting mouse models selectively removing 6TM variants in E11 knockout (KO) mice eliminated IBNtxA analgesia without affecting morphine analgesia. Conversely, morphine analgesia is lost in an exon 1 (E1) KO mouse that lacks all 7 transmembrane (7TM) variants but retains 6TM variant expression, while IBNtxA analgesia remains intact. Elimination of both E1 and E11 in an E1/E11 double KO mice abolishes both morphine and IBNtxA analgesia. Reconstituting expression of the 6TM variant mMOR-1G in E1/E11 KO mice through lentiviral expression rescued IBNtxA but not morphine analgesia. The aim of this study was to investigate the effect of lentiviral expression of the other 6TM variants in E1/E11 KO mice on IBNtxA analgesia. METHODS: Lentiviruses expressing 6TM variants were packaged in HEK293T cells, concentrated by ultracentrifugation, and intrathecally administered 3 times. Opioid analgesia was determined using a radiant-heat tail-flick assay. Expression of lentiviral 6TM variant messenger ribonucleic acids was examined by polymerase chain reaction (PCR) or quantitative PCR. RESULTS: All the 6TM variants restored IBNtxA analgesia in the E1/E11 KO mouse, while morphine remained inactive. Expression of lentiviral 6TM variants was confirmed by PCR or quantitative PCR. IBNtxA median effective dose values determined from cumulative dose–response studies in the rescued mice were indistinguishable from wild-type animals. IBNtxA analgesia was maintained for up to 33 weeks in the rescue mice and was readily antagonized by the opioid antagonist levallorphan. CONCLUSIONS: Our study demonstrated the pharmacological relevance of mouse 6TM variants in IBNtxA analgesia and established that a common functional core of the receptors corresponding to the transmembrane domains encoded by exons 2 and 3 is sufficient for activity. Thus, 6TM variants offer potential therapeutic targets for a distinct class of analgesics that are effective against broad-spectrum pain models without many side effects associated with traditional opioids.

Tetrapeptide endomorphin analogs require both full length and truncated splice variants of the mu opioid receptor gene Oprm1 for analgesia.

Structural Basis for Bifunctional Peptide Recognition at Human Δ-Opioid Receptor

Mediation of Opioid Analgesia by a Truncated Six Transmembrane G‐Protein‐Coupled Receptor

Mediation of Opioid Analgesia by a Truncated 6-Transmembrane GPCR.

Mediation of Buprenorphine Analgesia by a Combination of Traditional and Truncated Mu Opioid Receptor Splice Variants.

Truncated Mu Opioid GPCR Variant Involvement in Opioid-Dependent and Opioid-Independent Pain Modulatory Systems Within the CNS

Truncated Μ-Opioid Receptors with 6 Transmembrane Domains Are Essential for Opioid Analgesia

Alternatively Spliced Mu Opioid Receptor C Termini Impact the Diverse Actions of Morphine

Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions

Mediation of Exoticin Analgesia by a Truncated 6-Transmembrane of the Mu-Opioid Receptor

Methylation Products of 6Β- N-Heterocyclic Substituted Naltrexamine Derivatives As Potential Peripheral Opioid Receptor Modulators.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

The Opioid Ligand Binding of Human Mu-Opioid Receptor is Modulated by Novel Splice Variants of the Receptor.

Morphine Modulates the Expression of Mu-Opioid Receptor Exon 5-Associated Full-Length C-terminal Splice Variants by Upregulating Mir-378A-3p

To probe interaction of morphine and IBNtxA with 7TM and 6TM variants of the human μ-opioid receptor using all-atom molecular dynamics simulations with an explicit membrane

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Role of Mu-Opioid Agonist Efficacy on Antinociceptive Interactions Between Mu Agonists and the Nociceptin Opioid Peptide Agonist Ro 64-6198 in Rhesus Monkeys.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators